HCW Biologics IncHCWB
▲ PositiveCapitalrelevance
Regained Nasdaq compliance and announced reverse stock split to maintain listing
Impact on stocks 1
Biotech & Genomic Medicine
HCW Biologics IncHCW Biologics has regained compliance with Nasdaq's Bid Price Rule, according to a Nasdaq Hearings Panel decision on June 29, 2026. The company is now compliant with all continued listing rules and will be subject to a mandatory monitoring period through June 17, 2027. To ensure long-term compliance, HCW Biologics will implement a one-for-six reverse stock split on June 30, 2026.
HCW Biologics IncRegained Nasdaq compliance and announced reverse stock split to maintain listing